UY29615A1 - Compuestos quimicos iv - Google Patents
Compuestos quimicos ivInfo
- Publication number
- UY29615A1 UY29615A1 UY29615A UY29615A UY29615A1 UY 29615 A1 UY29615 A1 UY 29615A1 UY 29615 A UY29615 A UY 29615A UY 29615 A UY29615 A UY 29615A UY 29615 A1 UY29615 A1 UY 29615A1
- Authority
- UY
- Uruguay
- Prior art keywords
- chemical compounds
- solvates
- salts
- compounds
- prodrugs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 1
- 230000001906 cholesterol absorption Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501468 | 2005-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY29615A1 true UY29615A1 (es) | 2007-01-31 |
Family
ID=37570731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY29615A UY29615A1 (es) | 2005-06-22 | 2006-06-21 | Compuestos quimicos iv |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100048530A1 (enExample) |
| EP (1) | EP1896458A4 (enExample) |
| JP (1) | JP2008546770A (enExample) |
| KR (1) | KR20080033265A (enExample) |
| CN (1) | CN101223163A (enExample) |
| AR (1) | AR057383A1 (enExample) |
| AU (1) | AU2006259894A1 (enExample) |
| BR (1) | BRPI0611616A2 (enExample) |
| CA (1) | CA2609990A1 (enExample) |
| EC (1) | ECSP088103A (enExample) |
| IL (1) | IL187738A0 (enExample) |
| MX (1) | MX2007016486A (enExample) |
| NO (1) | NO20076196L (enExample) |
| RU (1) | RU2007147346A (enExample) |
| TW (1) | TW200726760A (enExample) |
| UY (1) | UY29615A1 (enExample) |
| WO (1) | WO2006137793A1 (enExample) |
| ZA (1) | ZA200710606B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
| AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| WO2008108486A1 (ja) * | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | １－ビアリールアゼチジノン誘導体 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| DE60229406D1 (de) * | 2001-09-21 | 2008-11-27 | Schering Corp | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) |
| GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| US6761509B2 (en) * | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
| US6960047B2 (en) * | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
| WO2004081002A1 (en) * | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7002008B2 (en) * | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
| WO2005046797A2 (en) * | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| ATE485267T1 (de) * | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| JP2007516287A (ja) * | 2003-12-23 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血症化合物 |
| KR100725758B1 (ko) * | 2004-03-30 | 2007-06-08 | 삼성광주전자 주식회사 | 전동 송풍기 및 이를 이용한 자동차용 전동 과급기 |
| US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| EP1807070A1 (en) * | 2004-09-29 | 2007-07-18 | Schering Corporation | Combinations of substituted azetidinones and cb1 antagonists |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
| TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
| US7498431B2 (en) * | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
| AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| WO2008033431A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
| WO2008108486A1 (ja) * | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | １－ビアリールアゼチジノン誘導体 |
-
2006
- 2006-06-20 AR ARP060102615A patent/AR057383A1/es not_active Application Discontinuation
- 2006-06-21 CA CA002609990A patent/CA2609990A1/en not_active Abandoned
- 2006-06-21 CN CNA2006800262826A patent/CN101223163A/zh active Pending
- 2006-06-21 US US11/993,479 patent/US20100048530A1/en not_active Abandoned
- 2006-06-21 WO PCT/SE2006/000762 patent/WO2006137793A1/en not_active Ceased
- 2006-06-21 MX MX2007016486A patent/MX2007016486A/es not_active Application Discontinuation
- 2006-06-21 BR BRPI0611616-7A patent/BRPI0611616A2/pt not_active Application Discontinuation
- 2006-06-21 JP JP2008518084A patent/JP2008546770A/ja not_active Withdrawn
- 2006-06-21 KR KR1020087001049A patent/KR20080033265A/ko not_active Withdrawn
- 2006-06-21 RU RU2007147346/04A patent/RU2007147346A/ru not_active Application Discontinuation
- 2006-06-21 UY UY29615A patent/UY29615A1/es not_active Application Discontinuation
- 2006-06-21 AU AU2006259894A patent/AU2006259894A1/en not_active Abandoned
- 2006-06-21 EP EP06747951A patent/EP1896458A4/en not_active Withdrawn
- 2006-06-22 TW TW095122510A patent/TW200726760A/zh unknown
-
2007
- 2007-11-28 IL IL187738A patent/IL187738A0/en unknown
- 2007-12-03 NO NO20076196A patent/NO20076196L/no not_active Application Discontinuation
- 2007-12-05 ZA ZA200710606A patent/ZA200710606B/xx unknown
-
2008
- 2008-01-11 EC EC2008008103A patent/ECSP088103A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1896458A1 (en) | 2008-03-12 |
| EP1896458A4 (en) | 2010-03-10 |
| AU2006259894A1 (en) | 2006-12-28 |
| RU2007147346A (ru) | 2009-07-27 |
| US20100048530A1 (en) | 2010-02-25 |
| JP2008546770A (ja) | 2008-12-25 |
| BRPI0611616A2 (pt) | 2011-05-31 |
| TW200726760A (en) | 2007-07-16 |
| AR057383A1 (es) | 2007-12-05 |
| ECSP088103A (es) | 2008-02-20 |
| IL187738A0 (en) | 2008-08-07 |
| MX2007016486A (es) | 2008-03-07 |
| CN101223163A (zh) | 2008-07-16 |
| WO2006137793A1 (en) | 2006-12-28 |
| NO20076196L (no) | 2008-02-29 |
| CA2609990A1 (en) | 2006-12-28 |
| KR20080033265A (ko) | 2008-04-16 |
| ZA200710606B (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29616A1 (es) | Compuestos químicos iii | |
| UY29617A1 (es) | Compuestos químicos vii | |
| PA8680701A1 (es) | Derivados de oxindol | |
| CR20110077A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
| ECSP078052A (es) | Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas | |
| UY28691A1 (es) | Derivados de difenilazetidona | |
| ECSP078051A (es) | Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas | |
| ECSP066302A (es) | Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| CY1111437T1 (el) | Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης | |
| ATE530524T1 (de) | Substituierte sulfonamid-derivate | |
| CR8831A (es) | Compuestos y metodos para el tratamiento de dislipidemia | |
| CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
| TW200726748A (en) | Chemical compounds II | |
| CL2012002526A1 (es) | Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca. | |
| DE602005009745D1 (de) | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür | |
| CY1113924T1 (el) | Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων | |
| ECSP088103A (es) | Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia | |
| ECSP088511A (es) | Agonistas del receptor del neuropeptido-2 | |
| NO20062357L (no) | Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer | |
| PT2056805E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular | |
| ECSP088114A (es) | Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia | |
| NI200700032A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| NO20082411L (no) | Heterocykliske amidforbindelser og anvendelse derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160817 |